Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL trial of rifaximin and lactulose for prevention of post-TIPS overt hepatic encephalopathy
2018-004323-37Phase 4Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hepatic encephalopathy (HE) comparing Xifaxan + Lactulose with Placebo control (2 arms). Primary endpoint: Development of overt hepatic encephalopathy within 3 months after TIPS placement. Started Jan 2019; status: active.
02
Drugs
rifaximinlactulose
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on 2018-004323-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004323-37.